---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-221604"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-08-25T23:59:59+00:00"
generated_at: "2026-06-11T03:47:22.034850+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody

## Summary
- On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).
- Novartis will cease enrolling patients in remaining active TGFß clinical studies and collect final data.
- XOMA licensed NIS793 to Novartis in September 2015; no milestones or royalties mentioned in the filing.
- NIS793 is investigational; efficacy/safety not established and no guarantee of commercial availability.

## SEC filing metadata
- accession: 0001193125-23-221604
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/0001193125-23-221604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523221604/d528666d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-221604
- JSON: https://secwatch.observer/filing/0001193125-23-221604.json
- Plain text: https://secwatch.observer/filing/0001193125-23-221604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.